CoChat
Sign Up
Cited by 95Cystic Fibrosis Research AdvancesDiabetes Management and ResearchDiabetes Treatment and Management

ISPAD Clinical Practice Consensus Guidelines 2022: Management of cystic fibrosis‐related diabetes in children and adolescents

Open access
Ode, Katie Larson, Ballman, Manfred, Battezzati, Alberto, Brennan, Amanda, Chan, Christine L., Hameed, Shihab, Ismail, Heba M., Kelly, Andrea +4 more·2022·Pediatric Diabetes
DOI 10.1111/pedi.13453PMC PMC10108242
Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/pedi.13453

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Cystic fibrosis-related diabetes (CFRD) is a common comorbidity in people with cystic fibrosis, occurring in about 20% of adolescents and 40-50% of adults.

    “Cystic fibrosis-related diabetes (CFRD) is a common comorbidity in people with cystic fibrosis, occurring in about 20% of adolescents and 40-50% of adults (127).”

    From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [127]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 175

  1. [1]Ibarra‐Gonzalez I, Campos‐Garcia FJ, Herrera‐Perez LDA, et al. Newborn cystic fibrosis screening in southeastern Mexico: birth prevalence and novel CFTR gene variants. J Med Screen. 2018; 25(3): 119‐ 125. doi: 10.1177/0969141317722808 28992757 · DOI
  2. [2]Chamnan P, Shine BS, Haworth CS, Bilton D, Adler AI. Diabetes as a determinant of mortality in cystic fibrosis. Diabetes Care. 2010; 33(2): 311‐ 316. doi: 10.2337/dc09-1215 19918014 PMC2809272 · DOI
  3. [3]Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med. 2000; 162(3 Pt 1): 891‐ 895. doi: 10.1164/ajrccm.162.3.9904075 10988101 · DOI
  4. [4]Lewis C, Blackman SM, Nelson A, et al. Diabetes‐related mortality in adults with cystic fibrosis. Role of genotype and sex. Am J Respir Crit Care Med. 2015; 191(2): 194‐ 200. doi: 10.1164/rccm.201403-0576OC 25479583 PMC4347432 · DOI
  5. [5]Moran A, Brunzell C, Cohen RC, et al. Clinical care guidelines for cystic fibrosis‐related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the pediatric Endocrine Society. Diabetes Care. 2010; 33(12): 2697‐ 2708. doi: 10.2337/dc10-1768 21115772 PMC2992215 · DOI
  6. [6]Lanng S, Hansen A, Thorsteinsson B, Nerup J, Koch C. Glucose tolerance in patients with cystic fibrosis: five year prospective study. BMJ. 1995; 311(7006): 655‐ 659. 7549632 PMC2551427
  7. [7]Chan CL, Hope E, Thurston J, et al. Hemoglobin A1c accurately predicts continuous glucose monitoring‐derived average glucose in youth and young adults with cystic fibrosis. Diabetes Care. 2018; 41(7): 1406‐ 1413. doi: 10.2337/dc17-2419 29674323 PMC6014540 · DOI
  8. [8]Moran A, Diem P, Klein DJ, Levitt MD, Robertson RP. Pancreatic endocrine function in cystic fibrosis. J Pediatr. 1991; 118(5): 715‐ 723. doi: 10.1016/s0022-3476(05)80032-0 2019925 · DOI
  9. [9]Wooldridge JL, Szczesniak RD, Fenchel MC, Elder DA. Insulin secretion abnormalities in exocrine pancreatic sufficient cystic fibrosis patients. J Cyst Fibros. 2015; 14(6): 792‐ 797. doi: 10.1016/j.jcf.2015.02.009 25754095 PMC4561041 · DOI
  10. [10]Moreau F, Weiller MA, Rosner V, et al. Continuous glucose monitoring in cystic fibrosis patients according to the glucose tolerance. Horm Metab Res. 2008; 40(7): 502‐ 506. doi: 10.1055/s-2008-1062723 18415892 · DOI
  11. [11]Dobson L, Sheldon CD, Hattersley AT. Conventional measures underestimate glycaemia in cystic fibrosis patients. Diabet Med. 2004; 21(7): 691‐ 696. doi: 10.1111/j.1464-5491.2004.01219.x 15209760 · DOI
  12. [12]O'Riordan SM, Hindmarsh P, Hill NR, et al. Validation of continuous glucose monitoring in children and adolescents with cystic fibrosis: a prospective cohort study. Diabetes Care. 2009; 32(6): 1020‐ 1022. doi: 10.2337/dc08-1925 19279304 PMC2681016 · DOI
  13. [13]Scheuing N, Holl RW, Dockter G, et al. Diabetes in cystic fibrosis: multicenter screening results based on current guidelines. PLoS One. 2013; 8(12): e81545. doi: 10.1371/journal.pone.0081545 24324701 PMC3855692 · DOI
  14. [14]Frohnert BI, Ode KL, Moran A, et al. Impaired fasting glucose in cystic fibrosis. Diabetes Care. 2010; 33(12): 2660‐ 2664. doi: 10.2337/dc10-0613 21115768 PMC2992208 · DOI
  15. [15]Schwarzenberg SJ, Thomas W, Olsen TW, et al. Microvascular complications in cystic fibrosis‐related diabetes. Diabetes Care. 2007; 30(5): 1056‐ 1061. doi: 10.2337/dc06-1576 17322485 · DOI
  16. [16]Piona C, Volpi S, Zusi C, et al. Glucose tolerance stages in cystic fibrosis are identified by a unique pattern of defects of Beta‐cell function. J Clin Endocrinol Metab. 2021; 106(4): e1793‐ e1802. doi: 10.1210/clinem/dgaa932 33331877 · DOI
  17. [17]Scheuing N, Holl RW, Dockter G, et al. High variability in oral glucose tolerance among 1,128 patients with cystic fibrosis: a multicenter screening study. PLoS One. 2014; 9(11): e112578. doi: 10.1371/journal.pone.0112578 25393021 PMC4231037 · DOI
  18. [18]Sterescu AE, Rhodes B, Jackson R, et al. Natural history of glucose intolerance in patients with cystic fibrosis: ten‐year prospective observation program. J Pediatr. 2010; 156(4): 613‐ 617. doi: 10.1016/j.jpeds.2009.10.019 19962154 · DOI
  19. [19]Hardin DS, Rice J, Cohen RC, Ellis KJ, Nick JA. The metabolic effects of pregnancy in cystic fibrosis. Obstet Gynecol. 2005; 106(2): 367‐ 375. doi: 10.1097/01.AOG.0000172421.04007.74 16055589 · DOI
  20. [20]Olesen HV, Drevinek P, Gulmans VA, et al. Cystic fibrosis related diabetes in Europe: prevalence, risk factors and outcome; Olesen et al. J Cyst Fibros. 2020; 19(2): 321‐ 327. doi: 10.1016/j.jcf.2019.10.009 31680042 · DOI · Paper page
  21. [21]Foundation CF. Annual Data Report. Cystic Fibrosis Foundation Patient Registry; 2020: 2021.
  22. [22]Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis‐related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009; 32(9): 1626‐ 1631. doi: 10.2337/dc09-0586 19542209 PMC2732133 · DOI
  23. [23]Iannucci A, Mukai K, Johnson D, Burke B. Endocrine pancreas in cystic fibrosis: an immunohistochemical study. Hum Pathol. 1984; 15(3): 278‐ 284. doi: 10.1016/s0046-8177(84)80191-4 6365738 · DOI
  24. [24]Lohr M, Goertchem P, Nizze H, et al. CF associated islet changes may provide a basis for diabetes. Virchows Archiv A Pathol Anat Histopathol. 1989; 414: 179‐ 185. 2492695
  25. [25]Couce M, O'Brien TD, Moran A, Roche PC, Butler PC. Diabetes mellitus in cystic fibrosis is characterized by islet amyloidosis. J Clin Endocrinol Metab. 1996; 81(3): 1267‐ 1272. doi: 10.1210/jcem.81.3.8772610 8772610 · DOI
  26. [26]Bogdani M, Blackman SM, Ridaura C, Bellocq JP, Powers AC, Aguilar‐Bryan L. Structural abnormalities in islets from very young children with cystic fibrosis may contribute to cystic fibrosis‐related diabetes. Sci Rep. 2017; 7: 17231. doi: 10.1038/s41598-017-17404-z 29222447 PMC5722914 · DOI
  27. [27]Hart NJ, Aramandla R, Poffenberger G, et al. Cystic fibrosis‐related diabetes is caused by islet loss and inflammation. JCI Insight. 2018; 3(8): e98240. doi: 10.1172/jci.insight.98240 29669939 PMC5931120 · DOI
  28. [28]Hull RL, Gibson RL, McNamara S, et al. Islet interleukin‐1beta Immunoreactivity is an early feature of cystic fibrosis that may contribute to beta‐cell failure. Diabetes Care. 2018; 41(4): 823‐ 830. doi: 10.2337/dc17-1387 29437698 PMC5860832 · DOI
  29. [29]Gottlieb PA, Yu L, Babu S, et al. No relation between cystic fibrosis‐related diabetes and type 1 diabetes autoimmunity. Diabetes Care. 2012; 35(8): e57. doi: 10.2337/dc11-2327 22826450 PMC3402258 · DOI
  30. [30]Bismuth E, Laborde K, Taupin P, et al. Glucose tolerance and insulin secretion, morbidity, and death in patients with cystic fibrosis. J Pediatr. 2008; 152(4): 540‐ 545, 545 e1. doi: 10.1016/j.jpeds.2007.09.025 18346512 · DOI
  31. [31]Holl RW, Wolf A, Thon A, et al. Insulin resistance with altered secretory kinetics and reduced proinsulin in cystic fibrosis patients. J Pediatr Gastroenterol Nutr. 1997; 25(2): 188‐ 193. doi: 10.1097/00005176-199708000-00010 9252906 · DOI
  32. [32]Lanng S, Thorsteinsson B, Pociot F, et al. Diabetes mellitus in cystic fibrosis: genetic and immunological markers. Acta Paediatr. 1993; 82(2): 150‐ 154. doi: 10.1111/j.1651-2227.1993.tb12628.x 8097419 · DOI
  33. [33]De Schepper J, Dab I, Derde MP, Loeb H. Oral glucose tolerance testing in cystic fibrosis: correlations with clinical parameters and glycosylated haemoglobin determinations. Eur J Pediatr. 1991; 150(6): 403‐ 406. doi: 10.1007/bf02093718 2040347 · DOI
  34. [34]Battezzati A, Mari A, Zazzeron L, et al. Identification of insulin secretory defects and insulin resistance during oral glucose tolerance test in a cohort of cystic fibrosis patients. Eur J Endocrinol. 2011; 165(1): 69‐ 76. doi: 10.1530/EJE-10-1003 21502328 · DOI
  35. [35]Hamdi I, Payne SJ, Barton DE, et al. Genotype analysis in cystic fibrosis in relation to the occurrence of diabetes mellitus. Clin Genet. 1993; 43(4): 186‐ 189. doi: 10.1111/j.1399-0004.1993.tb04445.x 7687208 · DOI
  36. [36]Yi Y, Norris AW, Wang K, et al. Abnormal glucose tolerance in infants and young children with cystic fibrosis. Am J Respir Crit Care Med. 2016; 194(8): 974‐ 980. doi: 10.1164/rccm.201512-2518OC 27447840 PMC5067820 · DOI
  37. [37]Sheikh S, Gudipaty L, De Leon DD, et al. Reduced beta‐cell secretory capacity in pancreatic‐insufficient, but not pancreatic‐sufficient, cystic fibrosis despite Normal glucose tolerance. Diabetes. 2017; 66(1): 134‐ 144. doi: 10.2337/db16-0394 27495225 PMC5204312 · DOI
  38. [38]Lanng S, Thorsteinsson B, Roder ME, Nerup J, Koch C. Insulin sensitivity and insulin clearance in cystic fibrosis patients with normal and diabetic glucose tolerance. Clin Endocrinol. 1994; 41(2): 217‐ 223. 7923827
  39. [39]Moran A, Pyzdrowski KL, Weinreb J, et al. Insulin sensitivity in cystic fibrosis. Diabetes. 1994; 43(8): 1020‐ 1026. doi: 10.2337/diab.43.8.1020 8039595 · DOI
  40. [40]Hardin DS, LeBlanc A, Para L, Seilheimer DK. Hepatic insulin resistance and defects in substrate utilization in cystic fibrosis. Diabetes. 1999; 48(5): 1082‐ 1087. doi: 10.2337/diabetes.48.5.1082 10331413 · DOI
  41. [41]Cucinotta D, De Luca F, Gigante A, et al. No changes of insulin sensitivity in cystic fibrosis patients with different degrees of glucose tolerance: an epidemiological and longitudinal study. Eur J Endocrinol. 1994; 130(3): 253‐ 258. doi: 10.1530/eje.0.1300253 8156098 · DOI
  42. [42]Colomba J, Boudreau V, Lehoux‐Dubois C, et al. The main mechanism associated with progression of glucose intolerance in older patients with cystic fibrosis is insulin resistance and not reduced insulin secretion capacity. J Cyst Fibros. 2019; 18(4): 551‐ 556. doi: 10.1016/j.jcf.2019.01.009 30711385 · DOI
  43. [43]Kutney KA, Sandouk Z, Desimone M, Moheet A. Obesity in cystic fibrosis. J Clin Transl Endocrinol. 2021; 26: 100276. doi: 10.1016/j.jcte.2021.100276 34868883 PMC8626670 · DOI
  44. [44]Lam AN, Aksit MA, Vecchio‐Pagan B, et al. Increased expression of anion transporter SLC26A9 delays diabetes onset in cystic fibrosis. J Clin Invest. 2020; 130(1): 272‐ 286. doi: 10.1172/JCI129833 31581148 PMC6934211 · DOI
  45. [45]Segerstolpe A, Palasantza A, Eliasson P, et al. Single‐cell transcriptome profiling of human pancreatic islets in health and type 2 diabetes. Cell Metab. 2016; 24(4): 593‐ 607. doi: 10.1016/j.cmet.2016.08.020 27667667 PMC5069352 · DOI · Paper page
  46. [46]Baron M, Veres A, Wolock SL, et al. A single‐cell transcriptomic map of the human and mouse pancreas reveals inter‐ and intra‐cell population structure. Cell Syst. 2016; 3(4): 346‐ 360 e4. doi: 10.1016/j.cels.2016.08.011 27667365 PMC5228327 · DOI · Paper page
  47. [47]Sun X, Yi Y, Xie W, et al. CFTR influences Beta cell function and insulin secretion through non‐cell autonomous exocrine‐derived factors. Endocrinology. 2017; 158(10): 3325‐ 3338. doi: 10.1210/en.2017-00187 28977592 PMC5659686 · DOI
  48. [48]Edlund A, Esguerra JL, Wendt A, Flodstrom‐Tullberg M, Eliasson L. CFTR and anoctamin 1 (ANO1) contribute to cAMP amplified exocytosis and insulin secretion in human and murine pancreatic beta‐cells. BMC Med. 2014; 12: 87. doi: 10.1186/1741-7015-12-87 24885604 PMC4035698 · DOI
  49. [49]Scully KJ, Marchetti P, Sawicki GS, et al. The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis. J Cyst Fibros. 2021; 21: 258‐ 263. doi: 10.1016/j.jcf.2021.09.001 34531155 PMC8918034 · DOI
  50. [50]Kelly A, De Leon DD, Sheikh S, et al. Islet hormone and Incretin secretion in cystic fibrosis after four months of Ivacaftor therapy. Am J Respir Crit Care Med. 2019; 199(3): 342‐ 351. doi: 10.1164/rccm.201806-1018OC 30130412 PMC6835076 · DOI
  51. [51]Volkova N, Moy K, Evans J, et al. Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries. J Cyst Fibros. 2020; 19(1): 68‐ 79. doi: 10.1016/j.jcf.2019.05.015 31196670 · DOI · Paper page
  52. [52]Misgault B, Chatron E, Reynaud Q, et al. Effect of one‐year lumacaftor‐ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients. J Cyst Fibros. 2020; 19(5): 712‐ 716. doi: 10.1016/j.jcf.2020.03.002 32201160 · DOI
  53. [53]Moheet A, Beisang D, Zhang L, et al. Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients. J Cyst Fibros. 2021; 20(2): 333‐ 338. doi: 10.1016/j.jcf.2020.09.001 32917547 PMC7937760 · DOI
  54. [54]Nichols DP, Donaldson SH, Frederick CA, et al. PROMISE: working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy. J Cyst Fibros. 2021; 20(2): 205‐ 212. doi: 10.1016/j.jcf.2021.02.003 33619012 PMC8686210 · DOI
  55. [55]Blackman SM, Hsu S, Ritter SE, et al. A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosis. Diabetologia. 2009; 52(9): 1858‐ 1865. doi: 10.1007/s00125-009-1436-2 19585101 PMC2877501 · DOI
  56. [56]Aksit MA, Pace RG, Vecchio‐Pagan B, et al. Genetic modifiers of cystic fibrosis‐related diabetes have extensive overlap with type 2 diabetes and related traits. J Clin Endocrinol Metab. 2020; 105(5): 1401‐ 1415. doi: 10.1210/clinem/dgz102 31697830 PMC7236628 · DOI
  57. [57]Blackman SM, Commander CW, Watson C, et al. Genetic modifiers of cystic fibrosis‐related diabetes. Diabetes. 2013; 62(10): 3627‐ 3635. doi: 10.2337/db13-0510 23670970 PMC3781476 · DOI
  58. [58]Derbel S, Doumaguet C, Hubert D, et al. Calpain 10 and development of diabetes mellitus in cystic fibrosis. J Cyst Fibros. 2006; 5(1): 47‐ 51. doi: 10.1016/j.jcf.2005.09.011 16377260 · DOI
  59. [59]Moran A, Milla C, Ducret R, Nair KS. Protein metabolism in clinically stable adult cystic fibrosis patients with abnormal glucose tolerance. Diabetes. 2001; 50(6): 1336‐ 1343. doi: 10.2337/diabetes.50.6.1336 11375334 · DOI
  60. [60]Rolon MA, Benali K, Munck A, et al. Cystic fibrosis‐related diabetes mellitus: clinical impact of prediabetes and effects of insulin therapy. Acta Paediatr. 2001; 90(8): 860‐ 867. 11529531
  61. [61]Braun AT, Merlo CA. Cystic fibrosis lung transplantation. Curr Opin Pulm Med. 2011; 17(6): 467‐ 472. doi: 10.1097/MCP.0b013e32834b8bdb 21897255 · DOI
  62. [62]Bradbury RA, Shirkhedkar D, Glanville AR, Campbell LV. Prior diabetes mellitus is associated with increased morbidity in cystic fibrosis patients undergoing bilateral lung transplantation: an ‘orphan’ area? A retrospective case‐control study. Intern Med J. 2009; 39(6): 384‐ 388. doi: 10.1111/j.1445-5994.2008.01786.x 19220548 · DOI
  63. [63]Belle‐van Meerkerk G, van de Graaf EA, Kwakkel‐van Erp JM, et al. Diabetes before and after lung transplantation in patients with cystic fibrosis and other lung diseases. Diabet Med. 2012; 29(8): e159‐ e162. doi: 10.1111/j.1464-5491.2012.03676.x 22486317 · DOI
  64. [64]Hadjiliadis D, Madill J, Chaparro C, et al. Incidence and prevalence of diabetes mellitus in patients with cystic fibrosis undergoing lung transplantation before and after lung transplantation. Clin Transpl. 2005; 19(6): 773‐ 778. doi: 10.1111/j.1399-0012.2005.00420.x 16313324 · DOI
  65. [65]Marshall BC, Butler SM, Stoddard M, Moran AM, Liou TG, Morgan WJ. Epidemiology of cystic fibrosis‐related diabetes. J Pediatr. 2005; 146(5): 681‐ 687. doi: 10.1016/j.jpeds.2004.12.039 15870674 · DOI
  66. [66]Finkelstein SM, Wielinski CL, Elliott GR, et al. Diabetes mellitus associated with cystic fibrosis. J Pediatr. 1988; 112(3): 373‐ 377. doi: 10.1016/s0022-3476(88)80315-9 3346774 · DOI
  67. [67]Rosenecker J, Hofler R, Steinkamp G, et al. Diabetes mellitus in patients with cystic fibrosis: the impact of diabetes mellitus on pulmonary function and clinical outcome. Eur J Med Res. 2001; 6(8): 345‐ 350. 11549516
  68. [68]Milla CE, Billings J, Moran A. Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis. Diabetes Care. 2005; 28(9): 2141‐ 2144. doi: 10.2337/diacare.28.9.2141 16123480 · DOI
  69. [69]Sims EJ, Green MW, Mehta A. Decreased lung function in female but not male subjects with established cystic fibrosis‐related diabetes. Diabetes Care. 2005; 28(7): 1581‐ 1587. doi: 10.2337/diacare.28.7.1581 15983304 · DOI
  70. [70]Kien CL, Zipf WB, Horswill CA, Denne SC, McCoy KS, O'Dorisio TM. Effects of feeding on protein turnover in healthy children and in children with cystic fibrosis. Am J Clin Nutr. 1996; 64(4): 608‐ 614. doi: 10.1093/ajcn/64.4.608 8839507 · DOI
  71. [71]Hardin DS, LeBlanc A, Lukenbaugh S, Para L, Seilheimer DK. Proteolysis associated with insulin resistance in cystic fibrosis. Pediatrics. 1998; 101(3 Pt 1): 433‐ 437. doi: 10.1542/peds.101.3.433 9481010 · DOI
  72. [72]Moran A, Basu R, Milla C, Jensen MD. Insulin regulation of free fatty acid kinetics in adult cystic fibrosis patients with impaired glucose tolerance. Metabolism. 2004; 53(11): 1467‐ 1472. doi: 10.1016/j.metabol.2004.06.015 15536603 · DOI
  73. [73]Brennan AL, Gyi KM, Wood DM, et al. Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis. J Cyst Fibros. 2007; 6(2): 101‐ 109. doi: 10.1016/j.jcf.2006.03.009 16844431 · DOI
  74. [74]Ntimbane T, Krishnamoorthy P, Huot C, et al. Oxidative stress and cystic fibrosis‐related diabetes: a pilot study in children. J Cyst Fibros. 2008; 7(5): 373‐ 384. doi: 10.1016/j.jcf.2008.01.004 18420468 · DOI
  75. [75]Suratwala D, Chan JS, Kelly A, et al. Nocturnal saturation and glucose tolerance in children with cystic fibrosis. Thorax. 2011; 66(7): 574‐ 578. doi: 10.1136/thx.2010.142141 21273357 · DOI
  76. [76]Hunt WR, Zughaier SM, Guentert DE, et al. Hyperglycemia impedes lung bacterial clearance in a murine model of cystic fibrosis‐related diabetes. Am J Physiol Lung Cell Mol Physiol. 2014; 306(1): L43‐ L49. doi: 10.1152/ajplung.00224.2013 24097557 PMC3920212 · DOI
  77. [77]Bengtson CD, He J, Kim MD, Salathe MA. Cystic fibrosis‐related diabetes is associated with worse lung function trajectory despite Ivacaftor use. Am J Respir Crit Care Med. 2021; 204(11): 1343‐ 1345. doi: 10.1164/rccm.202104-1060LE 34469275 PMC8786066 · DOI
  78. [78]Andersen HU, Lanng S, Pressler T, Laugesen CS, Mathiesen ER. Cystic fibrosis‐related diabetes: the presence of microvascular diabetes complications. Diabetes Care. 2006; 29(12): 2660‐ 2663. doi: 10.2337/dc06-0654 17130201 · DOI
  79. [79]Roberts R, Speight L, Lee J, et al. Retinal screening of patients with cystic fibrosis‐related diabetes in Wales ‐‐ a real eye opener. J Cyst Fibros. 2015; 14(2): 282‐ 284. doi: 10.1016/j.jcf.2014.07.014 25224328 · DOI
  80. [81]Onady GM, Farinet CL. An adult cystic fibrosis patient presenting with persistent dyspnea: case report. BMC Pulm Med. 2006; 6: 9. doi: 10.1186/1471-2466-6-9 16681861 PMC1471802 · DOI
  81. [82]Florea VG, Florea ND, Sharma R, et al. Right ventricular dysfunction in adult severe cystic fibrosis. Chest. 2000; 118(4): 1063‐ 1068. doi: 10.1378/chest.118.4.1063 11035678 · DOI
  82. [83]Perrin FM, Serino W. Ischaemic heart disease‐‐a new issue in cystic fibrosis? J R Soc Med. 2010; 103(Suppl 1): S44‐ S48. doi: 10.1258/jrsm.2010.s11010 20573670 PMC2905021 · DOI
  83. [84]Harindhanavudhi T, Wang Q, Dunitz J, Moran A, Moheet A. Prevalence and factors associated with overweight and obesity in adults with cystic fibrosis: a single‐center analysis. J Cyst Fibros. 2020; 19(1): 139‐ 145. doi: 10.1016/j.jcf.2019.10.004 31727452 PMC7680669 · DOI · Paper page
  84. [85]Gramegna A, Aliberti S, Contarini M, et al. Overweight and obesity in adults with cystic fibrosis: an Italian multicenter cohort study. J Cyst Fibros. 2021; 21: 111‐ 114. doi: 10.1016/j.jcf.2021.05.002 34053868 · DOI
  85. [86]Logue C, Smith C, Nath N, Beynon J, Tofeec K, Brennan AL. Prevalence of hypertension in cystic fibrosis. J Cyst Fibros. 2020; 19: S40.
  86. [87]Vizzardi E, Sciatti E, Bonadei I, et al. Elastic aortic properties in cystic fibrosis adults without cardiovascular risk factors: a case‐control study. Echocardiography. 2019; 36(6): 1118‐ 1122. doi: 10.1111/echo.14375 31148213 · DOI
  87. [88]Hull JH, Ansley L, Bolton CE, et al. The effect of exercise on large artery haemodynamics in cystic fibrosis. J Cyst Fibros. 2011; 10(2): 121‐ 127. doi: 10.1016/j.jcf.2010.12.001 21220217 · DOI
  88. [89]Figueroa V, Milla C, Parks EJ, Schwarzenberg SJ, Moran A. Abnormal lipid concentrations in cystic fibrosis. Am J Clin Nutr. 2002; 75(6): 1005‐ 1011. doi: 10.1093/ajcn/75.6.1005 12036806 · DOI
  89. [90]Georgiopoulou VV, Denker A, Bishop KL, et al. Metabolic abnormalities in adults with cystic fibrosis. Respirology. 2010; 15(5): 823‐ 829. doi: 10.1111/j.1440-1843.2010.01771.x 20497385 · DOI
  90. [91]Ishimo MC, Belson L, Ziai S, et al. Hypertriglyceridemia is associated with insulin levels in adult cystic fibrosis patients. J Cyst Fibros. 2013; 12(3): 271‐ 276. doi: 10.1016/j.jcf.2012.08.012 23017500 · DOI
  91. [92]Nash EF, Stephenson A, Helm EJ, et al. Impact of lung transplantation on serum lipids in adults with cystic fibrosis. J Heart Lung Transplant. 2011; 30(2): 188‐ 193. doi: 10.1016/j.healun.2010.08.024 20888257 · DOI
  92. [93]Bonhoure A, Potter KJ, Colomba J, et al. Peak glucose during an oral glucose tolerance test is associated with future diabetes risk in adults with cystic fibrosis. Diabetologia. 2021; 64(6): 1332‐ 1341. doi: 10.1007/s00125-021-05423-5 33693987 · DOI
  93. [94]Petersen MC, Begnel L, Wallendorf M, Litvin M. Effect of elexacaftor‐tezacaftor‐ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis. J Cyst Fibros. 2022; 21(2): 265‐ 271. doi: 10.1016/j.jcf.2021.11.012 34862121 PMC9999463 · DOI
  94. [95]Franck Thompson E, Watson D, Benoit CM, Landvik S, McNamara J. The association of pediatric cystic fibrosis‐related diabetes screening on clinical outcomes by center: a CF patient registry study. J Cyst Fibros. 2020; 19(2): 316‐ 320. doi: 10.1016/j.jcf.2019.07.010 31439463 · DOI · Paper page
  95. [96]Chan CL, Vigers T, Pyle L, Zeitler PS, Sagel SD, Nadeau KJ. Continuous glucose monitoring abnormalities in cystic fibrosis youth correlate with pulmonary function decline. J Cyst Fibros. 2018; 17(6): 783‐ 790. doi: 10.1016/j.jcf.2018.03.008 29580828 PMC6151303 · DOI
  96. [97]Elidottir H, Diemer S, Eklund E, Hansen CR. Abnormal glucose tolerance and lung function in children with cystic fibrosis. Comparing oral glucose tolerance test and continuous glucose monitoring. J Cyst Fibros. 2021; 20(5): 779‐ 784. doi: 10.1016/j.jcf.2021.01.002 33478894 · DOI
  97. [98]White H, Morton AM, Peckham DG, Conway SP. Dietary intakes in adult patients with cystic fibrosis–do they achieve guidelines? J Cyst Fibros. 2004; 3(1): 1‐ 7. doi: 10.1016/j.jcf.2003.12.002 15463880 · DOI
  98. [99]Cheung MS, Bridges NA, Prasad SA, et al. Growth in children with cystic fibrosis‐related diabetes. Pediatr Pulmonol. 2009; 44(12): 1223‐ 1225. doi: 10.1002/ppul.21127 19894249 · DOI
  99. [100]Ripa P, Robertson I, Cowley D, Harris M, Masters IB, Cotterill AM. The relationship between insulin secretion, the insulin‐like growth factor axis and growth in children with cystic fibrosis. Clin Endocrinol. 2002; 56(3): 383‐ 389. doi: 10.1046/j.1365-2265.2002.01484.x 11940051 · DOI
  100. [101]Hanna RM, Weiner DJ. Overweight and obesity in patients with cystic fibrosis: a center‐based analysis. Pediatr Pulmonol. 2015; 50(1): 35‐ 41. doi: 10.1002/ppul.23033 24757043 · DOI
  101. [103]Armaghanian N, Hetherington J, Parameswaran V, et al. Hypoglycemia in cystic fibrosis during an extended oral glucose tolerance test. Pediatr Pulmonol. 2020; 55(12): 3391‐ 3399. doi: 10.1002/ppul.25081 32955169 · DOI
  102. [104]Kilberg MJ, Harris C, Sheikh S, et al. Hypoglycemia and islet dysfunction following Oral glucose tolerance testing in pancreatic‐insufficient cystic fibrosis. J Clin Endocrinol Metab. 2020; 105(10): 3179‐ 3189. doi: 10.1210/clinem/dgaa448 32668452 PMC7755140 · DOI
  103. [105]Aitken ML, Szkudlinska MA, Boyko EJ, Ng D, Utzschneider KM, Kahn SE. Impaired counterregulatory responses to hypoglycaemia following oral glucose in adults with cystic fibrosis. Diabetologia. 2020; 63(5): 1055‐ 1065. doi: 10.1007/s00125-020-05096-6 31993716 PMC7150633 · DOI
  104. [106]Armaghanian N, Markovic TP, Brand‐Miller JC, Bye PTP, Moriarty CP, Steinbeck KS. Hypoglycaemia in cystic fibrosis: an analysis of a single centre adult cystic fibrosis clinic. J Cyst Fibros. 2018; 17(4): 542‐ 547. doi: 10.1016/j.jcf.2017.11.015 29254823 · DOI
  105. [107]Gaines H, Jones KR, Lim J, Medhi NF, Chen S, Scofield RH. Effect of CFTR modulator therapy on cystic fibrosis‐related diabetes. J Diabetes Complicat. 2021; 35(6): 107845. doi: 10.1016/j.jdiacomp.2020.107845 PMC8113061 33558149 · DOI
  106. [108]Radike K, Molz K, Holl RW, Poeter B, Hebestreit H, Ballmann M. Prognostic relevance of hypoglycemia following an oral glucose challenge for cystic fibrosis‐related diabetes. Diabetes Care. 2011; 34(4): e43. doi: 10.2337/dc10-2286 21447656 PMC3064065 · DOI
  107. [109]Mannik LA, Chang KA, Annoh PQK, et al. Prevalence of hypoglycemia during oral glucose tolerance testing in adults with cystic fibrosis and risk of developing cystic fibrosis‐related diabetes. J Cyst Fibros. 2018; 17(4): 536‐ 541. doi: 10.1016/j.jcf.2018.03.009 29680365 · DOI
  108. [110]Lanng S, Thorsteinsson B, Lund‐Andersen C, Nerup J, Schiotz PO, Koch C. Diabetes mellitus in Danish cystic fibrosis patients: prevalence and late diabetic complications. Acta Paediatr. 1994; 83(1): 72‐ 77. 8193478
  109. [111]Moran A, Pekow P, Grover P, et al. Insulin therapy to improve BMI in cystic fibrosis‐related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care. 2009; 32(10): 1783‐ 1788. doi: 10.2337/dc09-0585 19592632 PMC2752940 · DOI · Paper page
  110. [112]Mohan K, Israel KL, Miller H, Grainger R, Ledson MJ, Walshaw MJ. Long‐term effect of insulin treatment in cystic fibrosis‐related diabetes. Respiration. 2008; 76(2): 181‐ 186. doi: 10.1159/000110206 17960051 · DOI
  111. [113]Lanng S, Thorsteinsson B, Nerup J, Koch C. Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections. Acta Paediatr. 1994; 83(8): 849‐ 853. 7981562
  112. [114]Konrad K, Thon A, Fritsch M, et al. Comparison of cystic fibrosis‐related diabetes with type 1 diabetes based on a German/Austrian pediatric diabetes registry. Diabetes Care. 2013; 36(4): 879‐ 886. doi: 10.2337/dc12-0807 23238661 PMC3609515 · DOI
  113. [115]Schmid K, Fink K, Holl RW, Hebestreit H, Ballmann M. Predictors for future cystic fibrosis‐related diabetes by oral glucose tolerance test. J Cyst Fibros. 2014; 13(1): 80‐ 85. doi: 10.1016/j.jcf.2013.06.001 23809507 · DOI
  114. [116]Reynaud Q, Rabilloud M, Roche S, et al. Glucose trajectories in cystic fibrosis and their association with pulmonary function. J Cyst Fibros. 2018; 17(3): 400‐ 406. doi: 10.1016/j.jcf.2017.09.010 29037538 · DOI
  115. [117]Nguyen CQT, Denis MH, Chagnon M, Rabasa‐Lhoret R, Mailhot G. Abnormal glucose tolerance in a pediatric cystic fibrosis cohort: trends in clinical outcomes and associated factors in the preceding years. Nutr Metab Cardiovasc Dis. 2021; 31(1): 277‐ 285. doi: 10.1016/j.numecd.2020.07.044 32981797 · DOI
  116. [118]Ode KL, Frohnert B, Laguna T, et al. Oral glucose tolerance testing in children with cystic fibrosis. Pediatr Diabetes. 2010; 11(7): 487‐ 492. doi: 10.1111/j.1399-5448.2009.00632.x 20202149 PMC3856892 · DOI
  117. [119]Mozzillo E, Raia V, Fattorusso V, et al. Glucose derangements in very young children with cystic fibrosis and pancreatic insufficiency. Diabetes Care. 2012; 35(11): e78. doi: 10.2337/dc12-0459 23093689 PMC3476927 · DOI
  118. [120]Mozzillo E, Franceschi R, Piona C, et al. Diabetes and prediabetes in children with cystic fibrosis: a systematic review of the literature and recommendations of the Italian Society for pediatric endocrinology and diabetes (ISPED). Front Endocrinol (Lausanne). 2021; 12: 673539. doi: 10.3389/fendo.2021.673539 34017312 PMC8130616 · DOI
  119. [121]Chan CL, Pyle L, Vigers T, Zeitler PS, Nadeau KJ. Full the relationship between continuous glucose monitoring and OGTT in youth and young adults with cystic fibrosis. J Clin Endocrinol Metab. 2021; 107: e548‐ e560. doi: 10.1210/clinem/dgab692 PMC8764335 34537845 · DOI
  120. [122]Nyirjesy SC, Sheikh S, Hadjiliadis D, et al. Beta‐cell secretory defects are present in pancreatic insufficient cystic fibrosis with 1‐hour oral glucose tolerance test glucose >/=155 mg/dl. Pediatr Diabetes. 2018; 19(7): 1173‐ 1182. doi: 10.1111/pedi.12700 29885044 PMC6364976 · DOI
  121. [123]Sheikh S, Putt ME, Forde KA, Rubenstein RC, Kelly A. Elevation of one hour plasma glucose during oral glucose tolerance testing. Pediatr Pulmonol. 2015; 50(10): 963‐ 969. doi: 10.1002/ppul.23237 26087115 PMC6910238 · DOI
  122. [124]Brodsky J, Dougherty S, Makani R, Rubenstein RC, Kelly A. Elevation of 1‐hour plasma glucose during oral glucose tolerance testing is associated with worse pulmonary function in cystic fibrosis. Diabetes Care. 2011; 34(2): 292‐ 295. doi: 10.2337/dc10-1604 21228248 PMC3024336 · DOI
  123. [125]Hameed S, Morton JR, Jaffe A, et al. Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain. Diabetes Care. 2010; 33(2): 221‐ 226. doi: 10.2337/dc09-1492 19910502 PMC2809253 · DOI
  124. [126]Coriati A, Ziai S, Lavoie A, Berthiaume Y, Rabasa‐Lhoret R. The 1‐h oral glucose tolerance test glucose and insulin values are associated with markers of clinical deterioration in cystic fibrosis. Acta Diabetol. 2016; 53(3): 359‐ 366. doi: 10.1007/s00592-015-0791-3 26215312 · DOI
  125. [127]Prentice BJ, Chelliah A, Ooi CY, et al. Peak OGTT glucose is associated with lower lung function in young children with cystic fibrosis. J Cyst Fibros. 2020; 19(2): 305‐ 309. doi: 10.1016/j.jcf.2019.05.005 31126898 · DOI · Paper page
  126. [128]Potter KJ, Reynaud Q, Boudreau V, et al. Combined indeterminate and impaired glucose tolerance is a novel group at high risk of cystic fibrosis‐related diabetes. J Clin Endocrinol Metab. 2021; 106(10): e3901‐ e3910. doi: 10.1210/clinem/dgab384 34132785 · DOI
  127. [129]Tommerdahl KL, Brinton JT, Vigers T, et al. Delayed glucose peak and elevated 1‐hour glucose on the oral glucose tolerance test identify youth with cystic fibrosis with lower oral disposition index. J Cyst Fibros. 2020; 20: 2111‐ 2345. doi: 10.1016/j.jcf.2020.08.020 PMC7947033 32928701 · DOI
  128. [130]Potter KJ, Boudreau V, Shohoudi A, et al. Influence of pre‐diabetic and pancreatic exocrine states on pulmonary and nutritional status in adults with cystic fibrosis. J Cyst Fibros. 2021; 20(5): 803‐ 809. doi: 10.1016/j.jcf.2020.11.022 33353861 · DOI
  129. [131]Boudreau V, Reynaud Q, Denis A, et al. Impact of 1h oral glucose tolerance test on the clinical status of adult cystic fibrosis patients over a 4‐year period. PLoS One. 2021; 16(3): e0246897. doi: 10.1371/journal.pone.0246897 33735186 PMC7971459 · DOI
  130. [132]Gilmour JA, Sykes J, Etchells E, Tullis E. Cystic fibrosis‐related diabetes screening in adults: a gap analysis and evaluation of accuracy of glycated hemoglobin levels. Can J Diabetes. 2019; 43(1): 13‐ 18. doi: 10.1016/j.jcjd.2018.04.008 30173928 · DOI · Paper page
  131. [133]Coriati A, Elisha B, Virassamynaik S, et al. Diagnosis of cystic fibrosis‐related glucose abnormalities: can we shorten the standard oral glucose tolerance test? Appl Physiol Nutr Metab. 2013; 38(12): 1254‐ 1259. doi: 10.1139/apnm-2013-0022 24195626 · DOI
  132. [134]Boudreau V, Reynaud Q, Bonhoure A, Durieu I, Rabasa‐Lhoret R. Validation of a stepwise approach using glycated hemoglobin levels to reduce the number of required Oral glucose tolerance tests to screen for cystic fibrosis‐related diabetes in adults. Can J Diabetes. 2019; 43(3): 161‐ 162. doi: 10.1016/j.jcjd.2018.11.005 30713090 · DOI
  133. [135]Yung B, Kemp M, Hooper J, Hodson ME. Diagnosis of cystic fibrosis related diabetes: a selective approach in performing the oral glucose tolerance test based on a combination of clinical and biochemical criteria. Thorax. 1999; 54(1): 40‐ 43. doi: 10.1136/thx.54.1.40 10343630 PMC1745339 · DOI
  134. [136]Sheikh S, Localio AR, Kelly A, Rubenstein RC. Abnormal glucose tolerance and the 50‐gram glucose challenge test in cystic fibrosis. J Cyst Fibros. 2020; 19: 696‐ 699. doi: 10.1016/j.jcf.2020.01.003 31974039 PMC8293305 · DOI
  135. [137]Tommerdahl KL, Brinton JT, Vigers T, Nadeau KJ, Zeitler PS, Chan CL. Screening for cystic fibrosis‐related diabetes and prediabetes: evaluating 1,5‐anhydroglucitol, fructosamine, glycated albumin, and hemoglobin A1c. Pediatr Diabetes. 2019; 20(8): 1080‐ 1086. doi: 10.1111/pedi.12914 31469470 PMC7585935 · DOI
  136. [138]Boudreau V, Coriati A, Desjardins K, Rabasa‐Lhoret R. Glycated hemoglobin cannot yet be proposed as a screening tool for cystic fibrosis related diabetes. J Cyst Fibros. 2016; 15(2): 258‐ 260. doi: 10.1016/j.jcf.2016.02.005 26905501 · DOI
  137. [139]Darukhanavala A, Van Dessel F, Ho J, Hansen M, Kremer T, Alfego D. Use of hemoglobin A1c to identify dysglycemia in cystic fibrosis. PLoS One. 2021; 16(4): e0250036. doi: 10.1371/journal.pone.0250036 33882078 PMC8059836 · DOI · Paper page
  138. [140]Holl RW, Buck C, Babka C, Wolf A, Thon A. HbA1c is not recommended as a screening test for diabetes in cystic fibrosis. Diabetes Care. 2000; 23(1): 126. 10857983
  139. [141]Wagener JS, McNeill GC, Taussig LM, Corrigan JJ, Lemen R. Ferrokinetic and hematologic studies in cystic fibrosis patients. Am J Pediatr Hematol Oncol. 1983; 5(2): 153‐ 160. 6614395
  140. [142]Scully KJ, Sherwood JS, Martin K, et al. Continuous glucose monitoring and HbA1c in cystic fibrosis: clinical correlations and implications for CFRD diagnosis. J Clin Endocrinol Metab. 2021; 107: e1444‐ e1454. doi: 10.1210/clinem/dgab857 PMC8947309 34850006 · DOI
  141. [143]Racine F, Shohoudi A, Boudreau V, et al. Glycated hemoglobin as a first‐line screening test for cystic fibrosis related diabetes and impaired glucose tolerance in children with cystic fibrosis: a validation study. Can J Diabetes. 2021; 45(8): 768‐ 774. doi: 10.1016/j.jcjd.2021.03.005 33926819 · DOI
  142. [144]Burgess JC, Bridges N, Banya W, et al. HbA1c as a screening tool for cystic fibrosis related diabetes. J Cyst Fibros. 2016; 15(2): 251‐ 257. doi: 10.1016/j.jcf.2015.03.013 25869326 · DOI
  143. [145]Kinnaird KE, Sauerwein TJ. Lack of correlation between 1,5‐anhydroglucitol assay and oral glucose tolerance test in patients with cystic fibrosis. Endocr Pract. 2010; 16(2): 167‐ 170. doi: 10.4158/EP09149.OR 19833588 · DOI
  144. [146]Prentice BJ, Ooi CY, Verge CF, Hameed S, Widger J. Glucose abnormalities detected by continuous glucose monitoring are common in young children with cystic fibrosis. J Cyst Fibros. 2020; 19: 700‐ 703. doi: 10.1016/j.jcf.2020.02.009 32111453 · DOI
  145. [147]Leclercq A, Gauthier B, Rosner V, et al. Early assessment of glucose abnormalities during continuous glucose monitoring associated with lung function impairment in cystic fibrosis patients. J Cyst Fibros. 2014; 13(4): 478‐ 484. doi: 10.1016/j.jcf.2013.11.005 24359972 · DOI
  146. [148]Prentice BJ, Ooi CY, Strachan RE, et al. Early glucose abnormalities are associated with pulmonary inflammation in young children with cystic fibrosis. J Cyst Fibros. 2019; 18(6): 869‐ 873. doi: 10.1016/j.jcf.2019.03.010 31036487 · DOI
  147. [149]Giacobbe LE, Nguyen RH, Aguilera MN, et al. Effect of maternal cystic fibrosis genotype on diabetes in pregnancy. Obstet Gynecol. 2012; 120(6): 1394‐ 1399. doi: 10.1097/AOG.0b013e31826d7eca 23168765 · DOI
  148. [150]Oxman R, Roe AH, Jagdeesh U, Putman MS. Gestational and pregestational diabetes in pregnant women with cystic fibrosis. J Clin Transl Endocrinol. 2022; 27: 100289. doi: 10.1016/j.jcte.2021.100289 34984172 PMC8693285 · DOI
  149. [151]Sidhaye A, Goldswieg B, Kaminski B, Blackman SM, Kelly A. Endocrine complications after solid‐organ transplant in cystic fibrosis. J Cyst Fibros. 2019; 18(Suppl 2): S111‐ S119. doi: 10.1016/j.jcf.2019.08.019 31679722 · DOI
  150. [152]Freeman AJ, Sellers ZM, Mazariegos G, et al. A multidisciplinary approach to pretransplant and posttransplant management of cystic fibrosis‐associated liver disease. Liver Transpl. 2019; 25(4): 640‐ 657. doi: 10.1002/lt.25421 30697907 · DOI
  151. [153]Hasan S, Soltman S, Wood C, Blackman SM. The role of genetic modifiers, inflammation and CFTR in the pathogenesis of cystic fibrosis related diabetes. J Clin Transl Endocrinol. 2022; 27: 100287. doi: 10.1016/j.jcte.2021.100287 34976741 PMC8688704 · DOI
  152. [154]Norris JM, Johnson RK, Stene LC. Type 1 diabetes‐early life origins and changing epidemiology. Lancet Diabetes Endocrinol. 2020; 8(3): 226‐ 238. doi: 10.1016/S2213-8587(19)30412-7 31999944 PMC7332108 · DOI
  153. [155]Konrad K, Kapellen T, Lilienthal E, et al. Does beta‐cell autoimmunity play a role in cystic fibrosis‐related diabetes? Analysis based on the German/Austrian diabetes Patienten Verlaufsdokumentation registry. Diabetes Care. 2016; 39(8): 1338‐ 1344. doi: 10.2337/dc16-0020 27271187 · DOI
  154. [156]Skolnik K, Levy RD, Wilcox PG, Quon BS. Coronary artery disease in cystic fibrosis: an emerging concern? J Cyst Fibros. 2016; 15(6): e70‐ e71. doi: 10.1016/j.jcf.2016.09.010 27751792 · DOI
  155. [158]Koloušková S, Zemková D, Bartošová J, et al. Low‐dose insulin therapy in patients with cystic fibrosis and early‐stage insulinopenia prevents deterioration of lung function: a 3‐year prospective study. J Pediatr Endocrinol Metab. 2011; 24(7–8): 449‐ 454. doi: 10.1515/jpem.2011.050 21932580 · DOI
  156. [159]Sunni M, Bellin MD, Moran A. Exogenous insulin requirements do not differ between youth and adults with cystic fibrosis related diabetes. Pediatr Diabetes. 2013; 14(4): 295‐ 298. doi: 10.1111/pedi.12014 23350702 PMC3753224 · DOI
  157. [160]Hardin DS, Rice J, Rice M, Rosenblatt R. Use of the insulin pump in treat cystic fibrosis related diabetes. J Cyst Fibros. 2009; 8(3): 174‐ 178. doi: 10.1016/j.jcf.2008.12.001 19162566 · DOI
  158. [161]Sherwood JS, Jafri RZ, Balliro CA, et al. Automated glycemic control with the bionic pancreas in cystic fibrosis‐related diabetes: a pilot study. J Cyst Fibros. 2020; 19(1): 159‐ 161. doi: 10.1016/j.jcf.2019.08.002 31420176 PMC6995423 · DOI
  159. [162]Grover P, Thomas W, Moran A. Glargine versus NPH insulin in cystic fibrosis related diabetes. J Cyst Fibros. 2008; 7(2): 134‐ 136. doi: 10.1016/j.jcf.2007.07.004 17692577 PMC4801219 · DOI
  160. [163]Onady GM, Stolfi A. Insulin and oral agents for managing cystic fibrosis‐related diabetes. Cochrane Database Syst Rev. 2016; 4: Cd004730. doi: 10.1002/14651858.CD004730.pub4 27087121 · DOI
  161. [165]Onady GM, Stolfi A. Drug treatments for managing cystic fibrosis‐related diabetes. Cochrane Database Syst Rev. 2020; 10(10): Cd004730. doi: 10.1002/14651858.CD004730.pub5 33075159 PMC8094754 · DOI
  162. [166]Moran A. Cystic‐fibrosis‐related diabetes: time for oral drugs? Lancet Diabetes Endocrinol. 2018; 6(2): 85‐ 87. doi: 10.1016/s2213-8587(17)30407-2 29199114 · DOI
  163. [167]Aston‐Mourney K, Proietto J, Morahan G, Andrikopoulos S. Too much of a good thing: why it is bad to stimulate the beta cell to secrete insulin. Diabetologia. 2008; 51(4): 540‐ 545. doi: 10.1007/s00125-008-0930-2 18246324 · DOI
  164. [168]Nyirjesy SC, Peleckis AJ, Eiel JN, et al. Effects of GLP‐1 and GIP on islet function in glucose intolerant, pancreatic insufficient cystic fibrosis. Diabetes. 2022; 71: 2153‐ 2165. doi: 10.2337/db22-0399 35796669 PMC9501647 · DOI
  165. [169]Kelly A, Sheikh S, Stefanovski D, et al. Effect of Sitagliptin on islet function in pancreatic insufficient cystic fibrosis with abnormal glucose tolerance. J Clin Endocrinol Metab. 2021; 106(9): 2617‐ 2634. doi: 10.1210/clinem/dgab365 34406395 PMC8660013 · DOI
  166. [170]Bizzarri C, Lucidi V, Ciampalini P, Bella S, Russo B, Cappa M. Clinical effects of early treatment with insulin glargine in patients with cystic fibrosis and impaired glucose tolerance. J Endocrinol Investig. 2006; 29(3): RC1‐ RC4. doi: 10.1007/bf03345538 16682829 · DOI
  167. [171]Hameed S, Morton JR, Field PI, et al. Once daily insulin detemir in cystic fibrosis with insulin deficiency. Arch Dis Child. 2012; 97(5): 464‐ 467. doi: 10.1136/adc.2010.204636 21493664 · DOI
  168. [172]Mozzillo E, Franzese A, Valerio G, et al. One‐year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements. Pediatr Diabetes. 2009; 10(3): 162‐ 167. doi: 10.1111/j.1399-5448.2008.00451.x 19207231 · DOI
  169. [173]Zipf WB, Kien CL, Horswill CA, McCoy KS, O'Dorisio T, Pinyerd BL. Effects of tolbutamide on growth and body composition of nondiabetic children with cystic fibrosis. Pediatr Res. 1991; 30(4): 309‐ 314. doi: 10.1203/00006450-199110000-00004 1956712 · DOI
  170. [174]Culler FL, McKean LP, Buchanan CN, Caplan DB, Meacham LR. Glipizide treatment of patients with cystic fibrosis and impaired glucose tolerance. J Pediatr Gastroenterol Nutr. 1994; 18(3): 375‐ 378. doi: 10.1097/00005176-199404000-00021 8057224 · DOI
  171. [175]Tierney S, Webb K, Jones A, et al. Living with cystic fibrosis‐related diabetes or type 1 diabetes mellitus: a comparative study exploring health‐related quality of life and patients' reported experiences of hypoglycaemia. Chronic Illn. 2008; 4(4): 278‐ 288. doi: 10.1177/1742395308094240 19091936 · DOI
  172. [176]Havermans T, Vreys M, Proesmans M, De Boeck C. Assessment of agreement between parents and children on health‐related quality of life in children with cystic fibrosis. Child Care Health Dev. 2006; 32(1): 1‐ 7. doi: 10.1111/j.1365-2214.2006.00564.x 16398786 · DOI
  173. [177]Dill EJ, Dawson R, Sellers DE, Robinson WM, Sawicki GS. Longitudinal trends in health‐related quality of life in adults with cystic fibrosis. Chest. 2013; 144(3): 981‐ 989. doi: 10.1378/chest.12-1404 23670667 PMC3760745 · DOI
  174. [178]Kwong E, Desai S, Chong L, et al. The impact of cystic fibrosis‐related diabetes on health‐related quality of life. J Cyst Fibros. 2019; 18(5): 734‐ 736. doi: 10.1016/j.jcf.2019.03.007 30935840 · DOI
  175. [179]Abbott J, Morton AM, Hurley MA, Conway SP. Longitudinal impact of demographic and clinical variables on health‐related quality of life in cystic fibrosis. BMJ Open. 2015; 5(5): e007418. doi: 10.1136/bmjopen-2014-007418 PMC4442198 25991453 · DOI

Cited by

Sorted by citations

Authors
Ode, K. L., Ballman, M., Battezzati, A., Brennan, A., Chan, C. L., Hameed, S., Ismail, H. M., Kelly, A., Moran, A. M., Rabasa‐Lhoret, R., Saxby, N. A., & Craig, M. E.
Affiliations
  • University of Iowa (US)
  • Universitätsmedizin Rostock (DE)
  • University of Milan (IT)
  • Manchester University NHS Foundation Trust (GB)
  • Children's Hospital Colorado (US)
  • The University of Sydney (AU)
  • Indiana University Indianapolis (US)
  • Children's Hospital of Philadelphia (US)
  • University of Minnesota (US)
  • Division of Experiemental Medicine Montreal Clinical Research institute Montreal Canada
  • Women's and Children's Services Royal Hobart Hospital Hobart Tasmania Australia
Corresponding author
Ode, Katie Larson
ORCID
Venue
Pediatric Diabetes
Publisher
Hindawi Limited
Published
2022-12
Volume
23
Issue
8
Pages
1212-1228
ISSN
  • 1399-543X (ISSN-L)
  • 1399-5448
DOI
10.1111/pedi.13453
PMC
PMC10108242
OpenAlex
W4312179122
Cited by
95
References
3
Citations by year
2026: 33 · 2025: 34 · 2024: 16 · 2023: 12
FWCI
9.89
Type
journal article
Language
en
Open access
Licence
Locations
  • Pediatric Diabetes (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by-nc-nd)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK097830, P30DK097512)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
cystic fibrosis-related diabetes, cystic fibrosis, pediatric diabetes management, children and adolescents, insulin therapy, pancreatic enzyme replacement therapy
MeSH terms
Adolescent, Child, Cystic Fibrosis, Diabetes Mellitus, Humans, Cystic Fibrosis Transmembrane Conductance Regulator, Consensus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review